Skip to content

Restricted Cash at other companies

Incyte logo
IncyteINCY
$1.84M+10.3%
UroGen Pharma logo
UroGen PharmaURGN
$1.33M+23.3%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$102K-53.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$416K
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s restricted cash?
Tyra Biosciences, Inc. (TYRA) reported restricted cash of $884K in Q1 2026.
How has Tyra Biosciences, Inc.'s restricted cash changed year-over-year?
Tyra Biosciences, Inc.'s restricted cash decreased by 11.6% year-over-year, from $1M to $884K.
What is the long-term trend for Tyra Biosciences, Inc.'s restricted cash?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s restricted cash has grown at a 32.7% compound annual growth rate (CAGR), from $243K to $1M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.